DrugTimes001管理团队
DrugTimes001
102
文章
0
粉丝
-
美国上市公司寻找创新性ADC、双抗，您感兴趣吗？| 药时代BD项目
如果贵公司对这个机会感兴趣，请速速联系药时代BD团队！
-
American listed companies are looking for innovative ADCs and bispecific antibodies. Are you interested in this opportunity? | DrugTimes BD Project
Please contact the DrugTimes BD team as soon as possible!
-
诺和、礼来看好的ADC payload，您感兴趣吗？| 药时代BD项目
如果贵公司对新型NMTi payload感兴趣，请速速联系药时代BD团队！
-
Novo and Eli Lilly’s favored ADC payload, are you interested? | DrugTimes BD Project
If your company is interested in the new NMTi payload, please contact DrugTimes BD team as soon as possible!
-
Roche’s bispecific antibody therapy sets a new record as the “king of drugs” in ophthalmology
DrugTimes Team will follow up on this subject. Please stay tuned
-
Who will acquire Legend Bio for 13B to 15B USD? Could it be J&J?
Will J&J be the buyer? Please share your thoughts!~
-
As the 10th anniversary of approval approaches，Keytruda adds ‘potential’ performance to Merck
DrugTimes will follow up on this subject. Please stay tuned
-
Try again! Pfizer ‘revives’ its oral GLP-1RA
DrugTimes will present more reports. Please stay tuned
-
传奇生物确认收到并购邀约，股价大涨12%，市值近百亿美元，并购邀约引发市场关注
药时代将继续关注，及时报道。
-
The Past and Present of ‘Miraculous Medicine’ Roxadustat
Roxadustat is a domestically produced Class 1 innovative drug originating from the United …
点击查看更多
